MedTrace Logo

Evaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors.

NCT03163732 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 341

Last updated 2022-05-09

No results posted yet for this study

Summary

The PROFILER 02 program is a multicenter, randomized, prospective cohort study aiming to compare the clinical relevance of a large Next-generation sequencing (NGS) panel (FondationOne or FOne panel) versus a limited NGS panel (CONTROL or CTL panel) in patients with advanced solid tumors.

This study will allow adapting the therapeutic management of these patients, if needed, by giving them recommended therapies (commercialized or in ongoing clinical trials), based on the recommendations of the Molecular Tumor Board (MTB).

Conditions

  • Advanced Solid Tumor

Interventions

GENETIC

Blood and tumor samples

Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Olivier Olivier, MD · Centre Leon Berard

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-29
Primary Completion
2021-11-23
Completion
2021-11-23

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03163732 on ClinicalTrials.gov